Voyager Therapeutics Inc
NASDAQ:VYGR

Watchlist Manager
Voyager Therapeutics Inc Logo
Voyager Therapeutics Inc
NASDAQ:VYGR
Watchlist
Price: 5.69 USD -1.04%
Market Cap: 310.8m USD
Have any thoughts about
Voyager Therapeutics Inc?
Write Note

Operating Margin
Voyager Therapeutics Inc

7.3%
Current
-96%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.3%
=
Operating Profit
11.9m
/
Revenue
163.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Voyager Therapeutics Inc
NASDAQ:VYGR
313.6m USD
7%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
28%
US
Amgen Inc
NASDAQ:AMGN
142B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country US
Market Cap 313.6m USD
Operating Margin
7%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 310.2B USD
Operating Margin
28%
Country US
Market Cap 142B USD
Operating Margin
19%
Country US
Market Cap 115B USD
Operating Margin
38%
Country US
Market Cap 101.6B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78.5B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Voyager Therapeutics Inc
Glance View

Market Cap
310.3m USD
Industry
Biotechnology

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.

VYGR Intrinsic Value
5.02 USD
Overvaluation 12%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.3%
=
Operating Profit
11.9m
/
Revenue
163.8m
What is the Operating Margin of Voyager Therapeutics Inc?

Based on Voyager Therapeutics Inc's most recent financial statements, the company has Operating Margin of 7.3%.